Solid Biosciences Llc Stock Net Income
| SLDB Stock | USD 6.60 0.26 3.79% |
As of the 25th of January, Solid Biosciences has the Coefficient Of Variation of 2167.51, risk adjusted performance of 0.0424, and Semi Deviation of 4.51. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Solid Biosciences LLC, as well as the relationship between them.
Solid Biosciences Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 1.1559 | Earnings Share (2.48) | Quarterly Revenue Growth (1.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -112.2 M | -117.8 M | |
| Net Loss | -77.4 M | -81.3 M | |
| Net Loss | -112.2 M | -117.8 M | |
| Net Loss | (2.75) | (2.89) | |
| Net Income Per E B T | 0.88 | 0.76 |
Solid | Net Income | Build AI portfolio with Solid Stock |
Latest Solid Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Solid Biosciences LLC over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Solid Biosciences LLC financial statement analysis. It represents the amount of money remaining after all of Solid Biosciences LLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Solid Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Solid Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (124.7 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Solid Net Income Regression Statistics
| Arithmetic Mean | (58,892,763) | |
| Coefficient Of Variation | (79.92) | |
| Mean Deviation | 42,261,541 | |
| Median | (72,188,000) | |
| Standard Deviation | 47,067,910 | |
| Sample Variance | 2215.4T | |
| Range | 118.3M | |
| R-Value | (0.92) | |
| Mean Square Error | 355.5T | |
| R-Squared | 0.85 | |
| Slope | (8,591,204) | |
| Total Sum of Squares | 35446.2T |
Solid Net Income History
Other Fundumenentals of Solid Biosciences LLC
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Solid Biosciences Net Income component correlations
Solid Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Solid Biosciences is extremely important. It helps to project a fair market value of Solid Stock properly, considering its historical fundamentals such as Net Income. Since Solid Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Solid Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Solid Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Solid Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Solid Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Solid Biosciences.
| 10/27/2025 |
| 01/25/2026 |
If you would invest 0.00 in Solid Biosciences on October 27, 2025 and sell it all today you would earn a total of 0.00 from holding Solid Biosciences LLC or generate 0.0% return on investment in Solid Biosciences over 90 days. Solid Biosciences is related to or competes with Autolus Therapeutics, QuantumSi, Rocket Pharmaceuticals, LB Pharmaceuticals, Aura Biosciences, Benitec Biopharma, and Annexon. Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States More
Solid Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Solid Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Solid Biosciences LLC upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.88 | |||
| Information Ratio | 0.0314 | |||
| Maximum Drawdown | 21.63 | |||
| Value At Risk | (7.56) | |||
| Potential Upside | 11.36 |
Solid Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Solid Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Solid Biosciences' standard deviation. In reality, there are many statistical measures that can use Solid Biosciences historical prices to predict the future Solid Biosciences' volatility.| Risk Adjusted Performance | 0.0424 | |||
| Jensen Alpha | 0.0902 | |||
| Total Risk Alpha | (0.26) | |||
| Sortino Ratio | 0.0341 | |||
| Treynor Ratio | 0.111 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Solid Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Solid Biosciences January 25, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0424 | |||
| Market Risk Adjusted Performance | 0.121 | |||
| Mean Deviation | 3.82 | |||
| Semi Deviation | 4.51 | |||
| Downside Deviation | 4.88 | |||
| Coefficient Of Variation | 2167.51 | |||
| Standard Deviation | 5.3 | |||
| Variance | 28.13 | |||
| Information Ratio | 0.0314 | |||
| Jensen Alpha | 0.0902 | |||
| Total Risk Alpha | (0.26) | |||
| Sortino Ratio | 0.0341 | |||
| Treynor Ratio | 0.111 | |||
| Maximum Drawdown | 21.63 | |||
| Value At Risk | (7.56) | |||
| Potential Upside | 11.36 | |||
| Downside Variance | 23.84 | |||
| Semi Variance | 20.37 | |||
| Expected Short fall | (4.44) | |||
| Skewness | 0.261 | |||
| Kurtosis | 1.31 |
Solid Biosciences LLC Backtested Returns
Solid Biosciences appears to be unstable, given 3 months investment horizon. Solid Biosciences LLC owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.06, which indicates the firm had a 0.06 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Solid Biosciences LLC, which you can use to evaluate the volatility of the company. Please review Solid Biosciences' Risk Adjusted Performance of 0.0424, semi deviation of 4.51, and Coefficient Of Variation of 2167.51 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Solid Biosciences holds a performance score of 4. The entity has a beta of 2.11, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Solid Biosciences will likely underperform. Please check Solid Biosciences' semi variance, rate of daily change, and the relationship between the value at risk and kurtosis , to make a quick decision on whether Solid Biosciences' existing price patterns will revert.
Auto-correlation | 0.37 |
Below average predictability
Solid Biosciences LLC has below average predictability. Overlapping area represents the amount of predictability between Solid Biosciences time series from 27th of October 2025 to 11th of December 2025 and 11th of December 2025 to 25th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Solid Biosciences LLC price movement. The serial correlation of 0.37 indicates that just about 37.0% of current Solid Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.37 | |
| Spearman Rank Test | -0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 0.16 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Solid Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Solid Biosciences LLC reported net income of (124.7 Million). This is 136.54% lower than that of the Biotechnology sector and 278.02% lower than that of the Health Care industry. The net income for all United States stocks is 121.84% higher than that of the company.
Solid Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Solid Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Solid Biosciences could also be used in its relative valuation, which is a method of valuing Solid Biosciences by comparing valuation metrics of similar companies.Solid Biosciences is currently under evaluation in net income category among its peers.
Solid Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Solid Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Solid Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Solid Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Solid Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Solid Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Solid Biosciences' value.| Shares | Nantahala Capital Management, Llc | 2025-06-30 | 1.7 M | Alyeska Investment Group, L.p. | 2025-06-30 | 1.6 M | Mpm Oncology Impact Management Lp | 2025-06-30 | 1.6 M | Franklin Resources Inc | 2025-06-30 | 1.6 M | Geode Capital Management, Llc | 2025-06-30 | 1.5 M | Vestal Point Capital Lp | 2025-06-30 | 1.5 M | Point72 Asset Management, L.p. | 2025-06-30 | 1.3 M | Millennium Management Llc | 2025-06-30 | 1.1 M | Finepoint Capital Lp | 2025-06-30 | 961.3 K | Perceptive Advisors Llc | 2025-06-30 | 11.9 M | Bain Capital Life Sciences Investors, Llc | 2025-06-30 | 7.9 M |
Solid Fundamentals
| Return On Equity | -0.87 | ||||
| Return On Asset | -0.44 | ||||
| Current Valuation | 300 M | ||||
| Shares Outstanding | 77.91 M | ||||
| Shares Owned By Insiders | 0.55 % | ||||
| Shares Owned By Institutions | 99.45 % | ||||
| Number Of Shares Shorted | 10.03 M | ||||
| Price To Book | 2.36 X | ||||
| Price To Sales | 3.65 X | ||||
| Gross Profit | (96.43 M) | ||||
| EBITDA | (121.9 M) | ||||
| Net Income | (124.7 M) | ||||
| Cash And Equivalents | 162.88 M | ||||
| Cash Per Share | 1.44 X | ||||
| Total Debt | 24.18 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 7.85 X | ||||
| Book Value Per Share | 2.80 X | ||||
| Cash Flow From Operations | (100.01 M) | ||||
| Short Ratio | 10.71 X | ||||
| Earnings Per Share | (2.48) X | ||||
| Target Price | 15.23 | ||||
| Number Of Employees | 100 | ||||
| Beta | 2.69 | ||||
| Market Capitalization | 514.21 M | ||||
| Total Asset | 188.66 M | ||||
| Retained Earnings | (783.45 M) | ||||
| Working Capital | 127.05 M | ||||
| Net Asset | 188.66 M |
About Solid Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Solid Biosciences LLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Solid Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Solid Biosciences LLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Solid Biosciences LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Solid Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Solid Biosciences Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Solid Biosciences Llc Stock:Check out Solid Biosciences Piotroski F Score and Solid Biosciences Altman Z Score analysis. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.